#1
#1 out of 1
business1d ago
Assessing Takeda Pharmaceutical (TSE:4502) Valuation After Strong Multi‑Period Shareholder Returns
- Takeda’s 3-month return is 0.3% with a 1-year total return of 33.8%, signaling mixed momentum despite a positive longer-term trend.
- Simply Wall St places Takeda near a fair value of ¥5,590, suggesting slight overvaluation under one narrative.
- A DCF analysis argues for a very different story, with a fair value of ¥14,744.38 per share.
- The report cautions that equity outcomes depend on long-term cash flow assumptions and discounting.
- Investors are urged to weigh risks such as Actos-related litigation and pipeline setbacks.
- Takeda's portfolio includes Entyvio and Takhzyro among other brands across multiple therapeutic areas.
- The article emphasizes that the analysis is general in nature and not financial advice.
- The current price around ¥5,673 contrasts with the DCF-based fair value suggesting substantial upside.
- Takeda’s stock momentum shows near-term strength despite longer-term questions about growth potential.
- The piece highlights a list of related investment ideas including healthcare AI stocks and undervalued stocks.
Vote 0